The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...

The data suggest that, in the newborn piglet, the cerebral vasoconstrictor response to the parasympathetic neurotransmitter ACh results from muscarinic receptor activation and may be mediated by ...

Cobenfy has created a lot of excitement because it applies a new mechanism to treat schizophrenia – it targets muscarinic acetylcholine receptors, found in cell membranes. In particular ...

As per the Brain and Behavior Research Foundation, it combines two compounds called xanomeline and trospium chloride. This is ...

Muscarinic receptors are involved with neurotransmission via acetylcholine and glutamate, and are hypothesised to be dysfunctional in schizophrenia. Most drugs developed to treat schizophrenia to ...